Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BYSI BeyondSpring	$1.74 -0.4%	$1.53	$0.98 ▼ $2.97	$69.95M	0.13	26,470 shs	4,985 shs
CADL Candel Therapeutics	$5.53 -5.5%	$5.19	$3.79 ▼ $14.60	$273.06M	-0.92	1.46 million shs	1.10 million shs
GOSS Gossamer Bio	$1.12 -1.3%	$1.00	$0.50 ▼ $1.55	$253.44M	1.82	1.55 million shs	1.08 million shs
OCGN Ocugen	$0.84 +1.2%	$0.73	$0.52 ▼ $1.98	$246.56M	4.21	4.49 million shs	2.94 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BYSI BeyondSpring	0.00%	+0.35%	-3.07%	+2.66%	-37.14%
CADL Candel Therapeutics	0.00%	+1.84%	+13.09%	-38.42%	-37.09%
GOSS Gossamer Bio	0.00%	-7.08%	+5.19%	-9.35%	+90.89%
OCGN Ocugen	0.00%	-9.29%	+14.39%	+29.55%	-48.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	1.9344 of 5 stars	3.5	1.0	0.0	0.0	2.4	1.7	0.6
GOSS Gossamer Bio	4.0111 of 5 stars	3.5	2.0	0.0	4.7	3.5	1.7	0.0
OCGN Ocugen	0.8871 of 5 stars	3.5	0.0	0.0	0.0	1.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BYSI BeyondSpring	0.00	N/A	N/A	N/A
CADL Candel Therapeutics	3.00	Buy	$21.00	279.75% Upside
GOSS Gossamer Bio	3.00	Buy	$7.75	595.07% Upside
OCGN Ocugen	3.00	Buy	$6.00	610.65% Upside

Current Analyst Ratings Breakdown

Latest BYSI, GOSS, CADL, and OCGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/12/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
5/12/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/17/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
4/11/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
3/18/2025	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/14/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
3/14/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
3/6/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00
3/6/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00

(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BYSI BeyondSpring	$1.88M	37.29	N/A	N/A	($0.91) per share	-1.91
CADL Candel Therapeutics	$120K	2,308.91	N/A	N/A	$0.44 per share	12.57
GOSS Gossamer Bio	$124.59M	2.03	N/A	N/A	$0.28 per share	3.98
OCGN Ocugen	$4.52M	54.52	N/A	N/A	$0.16 per share	5.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BYSI BeyondSpring	-$21.03M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	-$37.94M	-$1.34	N/A	N/A	N/A	N/A	-629.29%	-173.39%	8/12/2025 (Estimated)
GOSS Gossamer Bio	-$179.82M	-$0.23	N/A	N/A	N/A	N/A	-127.28%	-22.12%	8/11/2025 (Estimated)
OCGN Ocugen	-$63.08M	-$0.19	N/A	N/A	N/A	-532.51%	-154.75%	-90.79%	8/14/2025 (Estimated)

Latest BYSI, GOSS, CADL, and OCGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
5/12/2025	Q1 2025	BYSI BeyondSpring	N/A	-$0.06	N/A	$0.11	N/A	N/A
5/9/2025	Q1 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	N/A	$1.48 million
3/18/2025	Q4 2024	GOSS Gossamer Bio	-$0.15	-$0.15	N/A	-$0.15	$7.02 million	$9.38 million
3/13/2025	Q4 2024	CADL Candel Therapeutics	-$0.23	-$0.40	-$0.17	-$0.40	N/A	N/A
3/5/2025	Q4 2024	OCGN Ocugen	-$0.05	-$0.05	N/A	-$0.05	$0.30 million	$0.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BYSI BeyondSpring	N/A	1.82	N/A
CADL Candel Therapeutics	N/A	1.18	1.18
GOSS Gossamer Bio	3.64	6.74	6.74
OCGN Ocugen	0.04	2.58	2.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BYSI BeyondSpring	40.29%
CADL Candel Therapeutics	13.93%
GOSS Gossamer Bio	81.23%
OCGN Ocugen	10.27%

Insider Ownership

Company	Insider Ownership
BYSI BeyondSpring	29.31%
CADL Candel Therapeutics	16.60%
GOSS Gossamer Bio	6.70%
OCGN Ocugen	4.42%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BYSI BeyondSpring	80	40.32 million	27.59 million	Optionable
CADL Candel Therapeutics	60	50.10 million	18.97 million	Optionable
GOSS Gossamer Bio	180	227.30 million	215.27 million	Optionable
OCGN Ocugen	80	292.03 million	278.82 million	Optionable

BYSI, GOSS, CADL, and OCGN Headlines

Recent News About These Companies

Jane Street Group LLC Purchases 357,891 Shares of Ocugen, Inc. (NASDAQ:OCGN)

June 1 at 3:14 AM | marketbeat.com

Ocugen’s OCU410ST receives Rare Pediatric Disease Designation for the treatment of ABCA4-associated retinopathies

May 27, 2025 | ophthalmologytimes.com

Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment

May 27, 2025 | msn.com

Ocugen, Inc. Receives FDA Rare Pediatric Disease Designation for OCU410ST in Treatment of ABCA4-Associated Retinopathies

May 27, 2025 | quiverquant.com

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 27, 2025 | globenewswire.com

Noble Financial Predicts Ocugen's Q2 Earnings (NASDAQ:OCGN)

May 16, 2025 | marketbeat.com

The Analyst Verdict: Ocugen In The Eyes Of 5 Experts

May 14, 2025 | nasdaq.com

Ocugen (NASDAQ:OCGN) Price Target Cut to $7.00 by Analysts at HC Wainwright

May 14, 2025 | marketbeat.com

Ocugen's (OCGN) "Buy" Rating Reiterated at Chardan Capital

May 14, 2025 | marketbeat.com

Ocugen (NASDAQ:OCGN) Releases Earnings Results, Beats Estimates By $0.01 EPS

May 13, 2025 | marketbeat.com

Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy

May 13, 2025 | msn.com

1OCGN : The Analyst Verdict: Ocugen In The Eyes Of 5 Experts

May 13, 2025 | benzinga.com

Ocugen, Inc. (NASDAQ:OCGN) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish

May 9, 2025 | msn.com

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 9, 2025 | globenewswire.com

A Look at Ocugen's Upcoming Earnings Report

May 9, 2025 | benzinga.com

Ocugen (OCGN) Projected to Post Earnings on Friday

May 6, 2025 | marketbeat.com

Ocugen to Host Q1 2025 Earnings Call and Business Update on May 9

May 5, 2025 | msn.com

OCUGEN Earnings Preview: Recent $OCGN Insider Trading, Hedge Fund Activity, and More

May 2, 2025 | nasdaq.com

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 2, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI, GOSS, CADL, and OCGN Company Descriptions

BeyondSpring NASDAQ:BYSI

$1.74 -0.01 (-0.38%)

Closing price 05/30/2025 03:50 PM Eastern

Extended Trading

$1.70 -0.03 (-1.73%)

As of 05/30/2025 07:42 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Candel Therapeutics NASDAQ:CADL

$5.53 -0.32 (-5.47%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$5.51 -0.02 (-0.36%)

As of 05/30/2025 07:25 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Gossamer Bio NASDAQ:GOSS

$1.12 -0.02 (-1.33%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.12 0.00 (0.00%)

As of 05/30/2025 06:38 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Ocugen NASDAQ:OCGN

$0.84 +0.01 (+1.21%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$0.84 -0.01 (-0.63%)

As of 05/30/2025 07:59 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time